Primary Care Providers Can Prescribe with Confidence
Information and resources are available to help primary care providers manage OUD with the help of medications for opioid use…
FDA Rationale for Recognition Decision: Voriconazole
FDA Rationale for Recognition Decision: Voriconazole
FDA Rationale for Piperacillin-Tazobactam Breakpoints for Enterobacterales
FDA Rationale for Piperacillin-Tazobactam Breakpoints for Enterobacterales
FDA Rationale for Piperacillin Tazobactam Breakpoints for Pseudomonas aeruginosa
FDA Rationale for Piperacillin Tazobactam Breakpoints for Pseudomonas aeruginosa
FDA Rationale for Recognition Decision: Daptomycin
FDA Rationale for Recognition Decision: Daptomycin
FDA Rationale for Breakpoints Recognition Decision: Polymyxins and Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter spp.
FDA Rationale for Breakpoints Recognition Decision: Polymyxins and Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter spp.
Rationale for FDA’s Position on Ceftazidime Breakpoints against Stenotrophomonas Maltophilia
Rationale for FDA’s Position on Ceftazidime Breakpoints against Stenotrophomonas Maltophilia
FDA Rationale for Recognition Decision: Ceftaroline fosamil
FDA Rationale for Recognition Decision: Ceftaroline fosamil
FDA Rationale for Recognition Decision: Cefiderocol
FDA Rationale for Recognition Decision: Cefiderocol
Setting and Implementing Standards for Narrow Therapeutic Index Drugs
CDER’s Narrow Therapeutic Index Drugs (NTI) working group works to resolve key NTI scientific and regulatory issues.